10月12日，美敦力盘中上涨3.14%，报91.245美元/股，成交额2.1亿美元。
消息面上，BTIG将美敦力目标价从100美元小幅调整至99美元，维持买入评级；此前Bernstein、UBS及Needham已先后上调目标价至112美元、110美元及114美元，FactSet统计的平均目标价达103.52美元，机构整体评级为超配。此外，美敦力宣布其MiniMed换股要约已获超额认购，进一步强化市场对糖尿病业务剥离顺利推进的预期。此前公司Affera Prism-2标测软件获FDA及CE认证，持续扩充心脏消融产品线，亦为股价提供基本面支撑。
美敦力总部位于爱尔兰都柏林，是世界上最大的医疗技术、服务和解决方案公司之一，为全球150多个国家的医院、医生和患者提供服务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.